BioNTech CEO Ugur Sahin Sells $6.84M in Shares Under Rule 10b5-1 Plan

Executive Summary

On September 24, 2026, BioNTech SE (BNTX) filed a Form 4 disclosing that Chief Executive Officer and 10% Owner Ugur Sahin sold a total of 69,000 Ordinary Shares over two consecutive days (September 23 and 24, 2026) for gross proceeds of approximately $6.84 million.

Transaction Breakdown

• September 23, 2026: Sold 30,000 shares directly at a weighted average price of $99.4027 ($2,982,081).
• September 24, 2026: Sold 39,000 shares directly at a weighted average price of $98.9913 ($3,860,661).
• Combined Volume & Price: 69,000 shares sold at a volume-weighted average price of approximately $99.17 per share ($6,842,741.70 total value).

Ownership Context and Rule 10b5-1 Details

• Pre-Scheduled Plan: The sales were executed under a Rule 10b5-1 trading plan adopted on June 3, 2026, mitigating concerns regarding opportunistic timing or non-public information.
• Remaining Holdings: Dr. Sahin directly retains 341,209 Ordinary Shares and indirectly holds 39,218,111 Ordinary Shares through Medine GmbH (where he is the sole shareholder). The sold shares represent less than 0.2% of his total direct and indirect equity stake, leaving his overall economic interest and control substantially intact.